期刊
WORLD JOURNAL OF GASTROENTEROLOGY
卷 27, 期 39, 页码 6527-6550出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i39.6527
关键词
Pancreatic cancer; Metabolism; DNA repair; Therapy-resistance; Immunotherapy
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States. This review discusses the molecular mechanisms involved in therapy resistance in PDAC, current approaches in targeting these mechanisms, lessons learned from the failure of immunotherapy in PDAC, and ongoing efforts to improve tumor's immunological response.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States. Although chemotherapeutic regimens such as gemcitabine+ nab-paclitaxel and FOLFIRINOX (FOLinic acid, 5-Fluroruracil, IRINotecan, and Oxaliplatin) significantly improve patient survival, the prevalence of therapy resistance remains a major roadblock in the success of these agents. This review discusses the molecular mechanisms that play a crucial role in PDAC therapy resistance and how a better understanding of these mechanisms has shaped clinical trials for pancreatic cancer chemotherapy. Specifically, we have discussed the metabolic alterations and DNA repair mechanisms observed in PDAC and current approaches in targeting these mechanisms. Our discussion also includes the lessons learned following the failure of immunotherapy in PDAC and current approaches underway to improve tumor's immunological response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据